Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

Affiliations

¹ Department of Radiology, University of Southern California, Los Angeles, California; jadvar@usc.edu thomas.hope@ucsf.edu.
² Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
³ University of Bologna, Bologna, Italy.
⁴ Department of Radiation Oncology, University of California, San Francisco, California.
⁵ Department of Urology, University of Virginia, Charlottesville, Virginia.
⁶ National Institutes of Health, Bethesda, Maryland.
⁷ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia.
⁸ Department of Radiation Oncology, Duke University, Durham, North Carolina.
⁹ Department of Urology, University of Washington, Seattle, Washington.
¹⁰ Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
¹¹ Department of Radiological Sciences, Johns Hopkins University, Baltimore, Maryland.
¹² Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina.
¹³ Department of Urology, University of Michigan, Ann Arbor, Michigan.
¹⁴ Department of Radiology, Loyola University, Maywood, Illinois.
¹⁵ Department of Medicine (Oncology), Stanford University, California; and.
¹⁶ Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Hossein Jadvar et al. J Nucl Med. 2022 Jan.

. 2022 Jan;63(1):59-68.

doi: 10.2967/jnumed.121.263262. Epub 2021 Sep 30.

¹ Department of Radiology, University of Southern California, Los Angeles, California; jadvar@usc.edu thomas.hope@ucsf.edu.
² Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
³ University of Bologna, Bologna, Italy.
⁴ Department of Radiation Oncology, University of California, San Francisco, California.
⁵ Department of Urology, University of Virginia, Charlottesville, Virginia.
⁶ National Institutes of Health, Bethesda, Maryland.
⁷ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia.
⁸ Department of Radiation Oncology, Duke University, Durham, North Carolina.
⁹ Department of Urology, University of Washington, Seattle, Washington.
¹⁰ Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
¹¹ Department of Radiological Sciences, Johns Hopkins University, Baltimore, Maryland.
¹² Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina.
¹³ Department of Urology, University of Michigan, Ann Arbor, Michigan.
¹⁴ Department of Radiology, Loyola University, Maywood, Illinois.
¹⁵ Department of Medicine (Oncology), Stanford University, California; and.
¹⁶ Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

No abstract available

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. - PubMed
1. Scher HI, Morris MJ, Stadler WM, et al.Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–1418. - PMC - PubMed
1. Schaeffer E, Srinivas S, Antonarakis ES, et al.NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw. 2021;19:134–143. - PubMed
1. Jadvar H. Imaging evaluation of prostate cancer with ¹⁸F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1):S5–S10. - PMC - PubMed
1. Fanti S, Minozzi S, Castellucci P, et al.PET/CT with ¹¹C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55–69. - PubMed